IASLC World Conference on Lung Cancer
Integration of Sexual Health Considerations Into Thoracic Oncology Care Is Critical
September 07, 2022
Article
Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.
Experimental Dosing Strategy With Sotorasib Plus Immunotherapy Helps Combat Hepatotoxicity in KRAS G12C+ NSCLC
August 31, 2022
Article
Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.
NSCLC Survivors Highlight Unmet Needs in Long-Term Experiences With Immunotherapy
August 23, 2022
Article
A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.
3.5-Year Follow-Up Finds Pembrolizumab/Etoposide Combo Still Effective in Untreated ES-SCLC
August 16, 2022
Article
Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.
Atezolizumab Signals OS Improvement in Patients with Resected NSCLC
August 15, 2022
Article
Phase 3 findings from the IMpower010 trial show that patients with resected non–small cell lung cancer may achieve an overall survival benefit with atezolizumab.
Larotrectinib Holds Ground as Effective Treatment in NTRK-Positive Lung Cancer
August 14, 2022
Article
Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.
Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLC
August 13, 2022
Article
Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.
Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC
August 09, 2022
Article
Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.
Neoadjuvant Triplet Regimen Safe, Effective in Patients With Resectable Mesothelioma
September 14, 2021
Article
Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.
Study Identifies High Mortality Rates in Patients with COVID-19 and Malignant Pleural Mesothelioma
September 11, 2021
Article
Patients with both COVID-19 and malignant pleural mesothelioma showed high rates of hospitalization and mortality.